The Protective Effect of Vitexin on Hypertensive Nephropathy Rats Article Swipe
Tingting Duan
,
Minyi Li
,
Ziyang Lin
,
Lanqing Meng
,
Mengqiu Li
,
Xia Tao
,
Xianlong Zhang
,
Guixuan Lin
,
Lufeng Yan
,
Mingjie Liang
,
Quan Zhu
,
Zhenghai Li
,
Junzheng Yang
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1159/000540618
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1159/000540618
Introduction: Vitexin is a natural flavonoid compound extracted from Vitex leaves or seeds, exhibiting various pharmacological activities including anticancer, antihypertensive, anti-inflammatory, and spasmolytic effects. However, its protective effects on hypertensive nephropathy (HN) and the underlying mechanisms remain unclear. Methods: Spontaneous hypertension rats were fed a high-sugar and high-fat diet for 8 weeks to induce the disease HN model. From the 5th week, the rats were administered vitexin via gavage. Blood pressure was measured biweekly using the tail-cuff method. Histopathological changes were assessed using HE staining, and biochemical analyses were performed to evaluate the effects of vitexin on HN rats. The underlying mechanisms of vitexin treatment were investigated through western blotting. Results: The data demonstrated that vitexin significantly lowered systolic, diastolic, and mean arterial pressures and ameliorated histopathological changes in HN rats. Biochemical analyses revealed that vitexin reduced the levels of creatinine (Cr), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), total protein (TP), low-density lipoprotein cholesterol (LDL-C), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), and advanced glycation end products (AGEs), while increasing the levels of albumin (ALB) and superoxide dismutase (SOD). Western blotting results indicated that vitexin treatment decreased the expression of TNF-α, IL-6, and nuclear factor kappa-B (NF-κB), while increasing the expression of SOD. Conclusion: The findings of this study suggest that vitexin exerts protective effects against HN, providing pharmacological evidence for its potential use in HN treatment.
Related Topics
Concepts
Vitexin
Nephropathy
Medicine
Renal injury
Hypertensive Nephropathy
Pharmacology
Internal medicine
Endocrinology
Chemistry
Renal function
Kidney
Diabetic nephropathy
Diabetes mellitus
Biochemistry
Flavonoid
Antioxidant
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1159/000540618
- OA Status
- gold
- Cited By
- 5
- References
- 30
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401112403
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401112403Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1159/000540618Digital Object Identifier
- Title
-
The Protective Effect of Vitexin on Hypertensive Nephropathy RatsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-30Full publication date if available
- Authors
-
Tingting Duan, Minyi Li, Ziyang Lin, Lanqing Meng, Mengqiu Li, Xia Tao, Xianlong Zhang, Guixuan Lin, Lufeng Yan, Mingjie Liang, Quan Zhu, Zhenghai Li, Junzheng YangList of authors in order
- Landing page
-
https://doi.org/10.1159/000540618Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1159/000540618Direct OA link when available
- Concepts
-
Vitexin, Nephropathy, Medicine, Renal injury, Hypertensive Nephropathy, Pharmacology, Internal medicine, Endocrinology, Chemistry, Renal function, Kidney, Diabetic nephropathy, Diabetes mellitus, Biochemistry, Flavonoid, AntioxidantTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 5Per-year citation counts (last 5 years)
- References (count)
-
30Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401112403 |
|---|---|
| doi | https://doi.org/10.1159/000540618 |
| ids.doi | https://doi.org/10.1159/000540618 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39079512 |
| ids.openalex | https://openalex.org/W4401112403 |
| fwci | 2.17842545 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000494 |
| mesh[1].descriptor_ui | D047310 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | pharmacology |
| mesh[1].descriptor_name | Apigenin |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D047310 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Apigenin |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D051381 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Rats |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D006977 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Hypertension, Renal |
| mesh[5].qualifier_ui | Q000473 |
| mesh[5].descriptor_ui | D006977 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pathology |
| mesh[5].descriptor_name | Hypertension, Renal |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D008297 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Male |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D011918 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Rats, Inbred SHR |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D009393 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Nephritis |
| mesh[9].qualifier_ui | Q000517 |
| mesh[9].descriptor_ui | D009393 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | prevention & control |
| mesh[9].descriptor_name | Nephritis |
| mesh[10].qualifier_ui | Q000473 |
| mesh[10].descriptor_ui | D009393 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pathology |
| mesh[10].descriptor_name | Nephritis |
| mesh[11].qualifier_ui | Q000187 |
| mesh[11].descriptor_ui | D001794 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | drug effects |
| mesh[11].descriptor_name | Blood Pressure |
| mesh[12].qualifier_ui | Q000378 |
| mesh[12].descriptor_ui | D016328 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | metabolism |
| mesh[12].descriptor_name | NF-kappa B |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000818 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Animals |
| mesh[14].qualifier_ui | Q000494 |
| mesh[14].descriptor_ui | D047310 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | pharmacology |
| mesh[14].descriptor_name | Apigenin |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D047310 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Apigenin |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D051381 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Rats |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D006977 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Hypertension, Renal |
| mesh[18].qualifier_ui | Q000473 |
| mesh[18].descriptor_ui | D006977 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | pathology |
| mesh[18].descriptor_name | Hypertension, Renal |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D008297 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Male |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D011918 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Rats, Inbred SHR |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D009393 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Nephritis |
| mesh[22].qualifier_ui | Q000517 |
| mesh[22].descriptor_ui | D009393 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | prevention & control |
| mesh[22].descriptor_name | Nephritis |
| mesh[23].qualifier_ui | Q000473 |
| mesh[23].descriptor_ui | D009393 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | pathology |
| mesh[23].descriptor_name | Nephritis |
| mesh[24].qualifier_ui | Q000187 |
| mesh[24].descriptor_ui | D001794 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | drug effects |
| mesh[24].descriptor_name | Blood Pressure |
| mesh[25].qualifier_ui | Q000378 |
| mesh[25].descriptor_ui | D016328 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | metabolism |
| mesh[25].descriptor_name | NF-kappa B |
| type | article |
| title | The Protective Effect of Vitexin on Hypertensive Nephropathy Rats |
| biblio.issue | 1 |
| biblio.volume | 49 |
| biblio.last_page | 762 |
| biblio.first_page | 753 |
| topics[0].id | https://openalex.org/T13013 |
| topics[0].field.id | https://openalex.org/fields/16 |
| topics[0].field.display_name | Chemistry |
| topics[0].score | 0.9761000275611877 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1605 |
| topics[0].subfield.display_name | Organic Chemistry |
| topics[0].display_name | Free Radicals and Antioxidants |
| topics[1].id | https://openalex.org/T10836 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9742000102996826 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Metabolomics and Mass Spectrometry Studies |
| topics[2].id | https://openalex.org/T13776 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9681000113487244 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2707 |
| topics[2].subfield.display_name | Complementary and alternative medicine |
| topics[2].display_name | Phytochemical and Pharmacological Studies |
| is_xpac | False |
| apc_list.value | 2530 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2780 |
| apc_paid.value | 2530 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2780 |
| concepts[0].id | https://openalex.org/C2779301978 |
| concepts[0].level | 4 |
| concepts[0].score | 0.6854135990142822 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q259075 |
| concepts[0].display_name | Vitexin |
| concepts[1].id | https://openalex.org/C2781184683 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6627981662750244 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1054718 |
| concepts[1].display_name | Nephropathy |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.5505799651145935 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2991844318 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5251309871673584 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q476921 |
| concepts[3].display_name | Renal injury |
| concepts[4].id | https://openalex.org/C2910852105 |
| concepts[4].level | 4 |
| concepts[4].score | 0.4990236759185791 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1434446 |
| concepts[4].display_name | Hypertensive Nephropathy |
| concepts[5].id | https://openalex.org/C98274493 |
| concepts[5].level | 1 |
| concepts[5].score | 0.48688045144081116 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[5].display_name | Pharmacology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.38152918219566345 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C134018914 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3741031289100647 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[7].display_name | Endocrinology |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.2843741178512573 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C159641895 |
| concepts[9].level | 2 |
| concepts[9].score | 0.24700665473937988 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q108377937 |
| concepts[9].display_name | Renal function |
| concepts[10].id | https://openalex.org/C2780091579 |
| concepts[10].level | 2 |
| concepts[10].score | 0.2253478467464447 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q9377 |
| concepts[10].display_name | Kidney |
| concepts[11].id | https://openalex.org/C2779922275 |
| concepts[11].level | 3 |
| concepts[11].score | 0.1646675169467926 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1129105 |
| concepts[11].display_name | Diabetic nephropathy |
| concepts[12].id | https://openalex.org/C555293320 |
| concepts[12].level | 2 |
| concepts[12].score | 0.12767767906188965 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[12].display_name | Diabetes mellitus |
| concepts[13].id | https://openalex.org/C55493867 |
| concepts[13].level | 1 |
| concepts[13].score | 0.12512081861495972 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[13].display_name | Biochemistry |
| concepts[14].id | https://openalex.org/C2779054382 |
| concepts[14].level | 3 |
| concepts[14].score | 0.06412309408187866 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q72185287 |
| concepts[14].display_name | Flavonoid |
| concepts[15].id | https://openalex.org/C2778004101 |
| concepts[15].level | 2 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q133948 |
| concepts[15].display_name | Antioxidant |
| keywords[0].id | https://openalex.org/keywords/vitexin |
| keywords[0].score | 0.6854135990142822 |
| keywords[0].display_name | Vitexin |
| keywords[1].id | https://openalex.org/keywords/nephropathy |
| keywords[1].score | 0.6627981662750244 |
| keywords[1].display_name | Nephropathy |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.5505799651145935 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/renal-injury |
| keywords[3].score | 0.5251309871673584 |
| keywords[3].display_name | Renal injury |
| keywords[4].id | https://openalex.org/keywords/hypertensive-nephropathy |
| keywords[4].score | 0.4990236759185791 |
| keywords[4].display_name | Hypertensive Nephropathy |
| keywords[5].id | https://openalex.org/keywords/pharmacology |
| keywords[5].score | 0.48688045144081116 |
| keywords[5].display_name | Pharmacology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.38152918219566345 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/endocrinology |
| keywords[7].score | 0.3741031289100647 |
| keywords[7].display_name | Endocrinology |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.2843741178512573 |
| keywords[8].display_name | Chemistry |
| keywords[9].id | https://openalex.org/keywords/renal-function |
| keywords[9].score | 0.24700665473937988 |
| keywords[9].display_name | Renal function |
| keywords[10].id | https://openalex.org/keywords/kidney |
| keywords[10].score | 0.2253478467464447 |
| keywords[10].display_name | Kidney |
| keywords[11].id | https://openalex.org/keywords/diabetic-nephropathy |
| keywords[11].score | 0.1646675169467926 |
| keywords[11].display_name | Diabetic nephropathy |
| keywords[12].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[12].score | 0.12767767906188965 |
| keywords[12].display_name | Diabetes mellitus |
| keywords[13].id | https://openalex.org/keywords/biochemistry |
| keywords[13].score | 0.12512081861495972 |
| keywords[13].display_name | Biochemistry |
| keywords[14].id | https://openalex.org/keywords/flavonoid |
| keywords[14].score | 0.06412309408187866 |
| keywords[14].display_name | Flavonoid |
| language | en |
| locations[0].id | doi:10.1159/000540618 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S167815962 |
| locations[0].source.issn | 1420-4096, 1423-0143 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1420-4096 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Kidney & Blood Pressure Research |
| locations[0].source.host_organization | https://openalex.org/P4310317820 |
| locations[0].source.host_organization_name | Karger Publishers |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310317820 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Kidney and Blood Pressure Research |
| locations[0].landing_page_url | https://doi.org/10.1159/000540618 |
| locations[1].id | pmid:39079512 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Kidney & blood pressure research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39079512 |
| locations[2].id | pmh:oai:doaj.org/article:ee2daa979d9641c8841dec87638993dc |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Kidney & Blood Pressure Research (2024) |
| locations[2].landing_page_url | https://doaj.org/article/ee2daa979d9641c8841dec87638993dc |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5101662199 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9155-3799 |
| authorships[0].author.display_name | Tingting Duan |
| authorships[0].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Tingting Duan |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[1].author.id | https://openalex.org/A5034753099 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5372-0365 |
| authorships[1].author.display_name | Minyi Li |
| authorships[1].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Minyi Li |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[2].author.id | https://openalex.org/A5044094458 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-7228-6851 |
| authorships[2].author.display_name | Ziyang Lin |
| authorships[2].countries | CN |
| authorships[2].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I117532281 |
| authorships[2].affiliations[1].raw_affiliation_string | The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China. |
| authorships[2].institutions[0].id | https://openalex.org/I117532281 |
| authorships[2].institutions[0].ror | https://ror.org/03qb7bg95 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I117532281 |
| authorships[2].institutions[0].country_code | CN |
| authorships[2].institutions[0].display_name | Guangzhou University of Chinese Medicine |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ziyang Lin |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China., The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China. |
| authorships[3].author.id | https://openalex.org/A5100573802 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Lanqing Meng |
| authorships[3].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lanqing Meng |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[4].author.id | https://openalex.org/A5026369376 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5236-9895 |
| authorships[4].author.display_name | Mengqiu Li |
| authorships[4].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mengqiu Li |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[5].author.id | https://openalex.org/A5100623727 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-0809-8968 |
| authorships[5].author.display_name | Xia Tao |
| authorships[5].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Tao Xia |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[6].author.id | https://openalex.org/A5100772317 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0718-8993 |
| authorships[6].author.display_name | Xianlong Zhang |
| authorships[6].countries | CN |
| authorships[6].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I117532281 |
| authorships[6].affiliations[1].raw_affiliation_string | The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China. |
| authorships[6].institutions[0].id | https://openalex.org/I117532281 |
| authorships[6].institutions[0].ror | https://ror.org/03qb7bg95 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I117532281 |
| authorships[6].institutions[0].country_code | CN |
| authorships[6].institutions[0].display_name | Guangzhou University of Chinese Medicine |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Xianlong Zhang |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China., The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China. |
| authorships[7].author.id | https://openalex.org/A5053289515 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Guixuan Lin |
| authorships[7].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Guixuan Lin |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[8].author.id | https://openalex.org/A5060124320 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-6772-4615 |
| authorships[8].author.display_name | Lufeng Yan |
| authorships[8].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Lufeng Yan |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[9].author.id | https://openalex.org/A5069867644 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Mingjie Liang |
| authorships[9].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Mingjie Liang |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[10].author.id | https://openalex.org/A5078836551 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-4042-3959 |
| authorships[10].author.display_name | Quan Zhu |
| authorships[10].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Quan Zhu |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[11].author.id | https://openalex.org/A5043828504 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-2563-7636 |
| authorships[11].author.display_name | Zhenghai Li |
| authorships[11].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Zhenghai Li |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[12].author.id | https://openalex.org/A5085375811 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-9992-3179 |
| authorships[12].author.display_name | Junzheng Yang |
| authorships[12].affiliations[0].raw_affiliation_string | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Junzheng Yang |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Guangdong Nephrotic Drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1159/000540618 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The Protective Effect of Vitexin on Hypertensive Nephropathy Rats |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13013 |
| primary_topic.field.id | https://openalex.org/fields/16 |
| primary_topic.field.display_name | Chemistry |
| primary_topic.score | 0.9761000275611877 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1605 |
| primary_topic.subfield.display_name | Organic Chemistry |
| primary_topic.display_name | Free Radicals and Antioxidants |
| related_works | https://openalex.org/W2524889084, https://openalex.org/W2386672106, https://openalex.org/W2020845442, https://openalex.org/W3142048114, https://openalex.org/W2275735940, https://openalex.org/W2370503546, https://openalex.org/W2074201842, https://openalex.org/W1969653270, https://openalex.org/W4388337771, https://openalex.org/W3042687315 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 5 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1159/000540618 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S167815962 |
| best_oa_location.source.issn | 1420-4096, 1423-0143 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1420-4096 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Kidney & Blood Pressure Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310317820 |
| best_oa_location.source.host_organization_name | Karger Publishers |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310317820 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Kidney and Blood Pressure Research |
| best_oa_location.landing_page_url | https://doi.org/10.1159/000540618 |
| primary_location.id | doi:10.1159/000540618 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S167815962 |
| primary_location.source.issn | 1420-4096, 1423-0143 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1420-4096 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Kidney & Blood Pressure Research |
| primary_location.source.host_organization | https://openalex.org/P4310317820 |
| primary_location.source.host_organization_name | Karger Publishers |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310317820 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Kidney and Blood Pressure Research |
| primary_location.landing_page_url | https://doi.org/10.1159/000540618 |
| publication_date | 2024-07-30 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2983691809, https://openalex.org/W3108143804, https://openalex.org/W3121706821, https://openalex.org/W2038676563, https://openalex.org/W2125511313, https://openalex.org/W3197820293, https://openalex.org/W2042093143, https://openalex.org/W4353071191, https://openalex.org/W2141103686, https://openalex.org/W4321478252, https://openalex.org/W4297257119, https://openalex.org/W861690976, https://openalex.org/W1550979862, https://openalex.org/W2115999849, https://openalex.org/W2014967627, https://openalex.org/W4302299455, https://openalex.org/W4396661140, https://openalex.org/W2899773405, https://openalex.org/W4238022675, https://openalex.org/W2976586219, https://openalex.org/W2163568406, https://openalex.org/W2160382989, https://openalex.org/W2052914045, https://openalex.org/W2018354913, https://openalex.org/W3202333780, https://openalex.org/W4205141291, https://openalex.org/W3014527183, https://openalex.org/W3001827567, https://openalex.org/W2538132594, https://openalex.org/W2161654600 |
| referenced_works_count | 30 |
| abstract_inverted_index.8 | 50 |
| abstract_inverted_index.a | 3, 44 |
| abstract_inverted_index.HE | 83 |
| abstract_inverted_index.HN | 56, 97, 129, 229 |
| abstract_inverted_index.in | 128, 228 |
| abstract_inverted_index.is | 2 |
| abstract_inverted_index.of | 94, 102, 139, 176, 193, 205, 210 |
| abstract_inverted_index.on | 28, 96 |
| abstract_inverted_index.or | 11 |
| abstract_inverted_index.to | 52, 90 |
| abstract_inverted_index.5th | 60 |
| abstract_inverted_index.HN, | 220 |
| abstract_inverted_index.The | 99, 111, 208 |
| abstract_inverted_index.and | 21, 32, 46, 85, 120, 124, 166, 179, 196 |
| abstract_inverted_index.end | 169 |
| abstract_inverted_index.fed | 43 |
| abstract_inverted_index.for | 49, 224 |
| abstract_inverted_index.its | 25, 225 |
| abstract_inverted_index.the | 33, 54, 59, 62, 75, 92, 137, 174, 191, 203 |
| abstract_inverted_index.use | 227 |
| abstract_inverted_index.via | 67 |
| abstract_inverted_index.was | 71 |
| abstract_inverted_index.(HN) | 31 |
| abstract_inverted_index.From | 58 |
| abstract_inverted_index.SOD. | 206 |
| abstract_inverted_index.data | 112 |
| abstract_inverted_index.diet | 48 |
| abstract_inverted_index.from | 8 |
| abstract_inverted_index.mean | 121 |
| abstract_inverted_index.rats | 41, 63 |
| abstract_inverted_index.that | 114, 134, 187, 214 |
| abstract_inverted_index.this | 211 |
| abstract_inverted_index.urea | 143 |
| abstract_inverted_index.were | 42, 64, 80, 88, 105 |
| abstract_inverted_index.(ALB) | 178 |
| abstract_inverted_index.(Cr), | 141 |
| abstract_inverted_index.(TC), | 148 |
| abstract_inverted_index.(TG), | 150 |
| abstract_inverted_index.(TP), | 153 |
| abstract_inverted_index.Blood | 69 |
| abstract_inverted_index.IL-6, | 195 |
| abstract_inverted_index.Vitex | 9 |
| abstract_inverted_index.blood | 142 |
| abstract_inverted_index.rats. | 98, 130 |
| abstract_inverted_index.study | 212 |
| abstract_inverted_index.total | 146, 151 |
| abstract_inverted_index.tumor | 158 |
| abstract_inverted_index.using | 74, 82 |
| abstract_inverted_index.week, | 61 |
| abstract_inverted_index.weeks | 51 |
| abstract_inverted_index.while | 172, 201 |
| abstract_inverted_index.(BUN), | 145 |
| abstract_inverted_index.(MDA), | 165 |
| abstract_inverted_index.(SOD). | 182 |
| abstract_inverted_index.exerts | 216 |
| abstract_inverted_index.factor | 198 |
| abstract_inverted_index.induce | 53 |
| abstract_inverted_index.leaves | 10 |
| abstract_inverted_index.levels | 138, 175 |
| abstract_inverted_index.model. | 57 |
| abstract_inverted_index.remain | 36 |
| abstract_inverted_index.seeds, | 12 |
| abstract_inverted_index.(AGEs), | 171 |
| abstract_inverted_index.(IL-6), | 163 |
| abstract_inverted_index.TNF-α, | 194 |
| abstract_inverted_index.Vitexin | 1 |
| abstract_inverted_index.Western | 183 |
| abstract_inverted_index.against | 219 |
| abstract_inverted_index.albumin | 177 |
| abstract_inverted_index.changes | 79, 127 |
| abstract_inverted_index.disease | 55 |
| abstract_inverted_index.effects | 27, 93, 218 |
| abstract_inverted_index.gavage. | 68 |
| abstract_inverted_index.kappa-B | 199 |
| abstract_inverted_index.lowered | 117 |
| abstract_inverted_index.method. | 77 |
| abstract_inverted_index.natural | 4 |
| abstract_inverted_index.nuclear | 197 |
| abstract_inverted_index.protein | 152 |
| abstract_inverted_index.reduced | 136 |
| abstract_inverted_index.results | 185 |
| abstract_inverted_index.suggest | 213 |
| abstract_inverted_index.through | 107 |
| abstract_inverted_index.various | 14 |
| abstract_inverted_index.vitexin | 66, 95, 103, 115, 135, 188, 215 |
| abstract_inverted_index.western | 108 |
| abstract_inverted_index.(LDL-C), | 157 |
| abstract_inverted_index.However, | 24 |
| abstract_inverted_index.Methods: | 38 |
| abstract_inverted_index.Results: | 110 |
| abstract_inverted_index.advanced | 167 |
| abstract_inverted_index.analyses | 87, 132 |
| abstract_inverted_index.arterial | 122 |
| abstract_inverted_index.assessed | 81 |
| abstract_inverted_index.biweekly | 73 |
| abstract_inverted_index.blotting | 184 |
| abstract_inverted_index.compound | 6 |
| abstract_inverted_index.effects. | 23 |
| abstract_inverted_index.evaluate | 91 |
| abstract_inverted_index.evidence | 223 |
| abstract_inverted_index.findings | 209 |
| abstract_inverted_index.high-fat | 47 |
| abstract_inverted_index.measured | 72 |
| abstract_inverted_index.necrosis | 159 |
| abstract_inverted_index.nitrogen | 144 |
| abstract_inverted_index.pressure | 70 |
| abstract_inverted_index.products | 170 |
| abstract_inverted_index.revealed | 133 |
| abstract_inverted_index.unclear. | 37 |
| abstract_inverted_index.(NF-κB), | 200 |
| abstract_inverted_index.(TNF-α), | 161 |
| abstract_inverted_index.blotting. | 109 |
| abstract_inverted_index.decreased | 190 |
| abstract_inverted_index.dismutase | 181 |
| abstract_inverted_index.extracted | 7 |
| abstract_inverted_index.factor-α | 160 |
| abstract_inverted_index.flavonoid | 5 |
| abstract_inverted_index.glycation | 168 |
| abstract_inverted_index.including | 17 |
| abstract_inverted_index.indicated | 186 |
| abstract_inverted_index.performed | 89 |
| abstract_inverted_index.potential | 226 |
| abstract_inverted_index.pressures | 123 |
| abstract_inverted_index.providing | 221 |
| abstract_inverted_index.staining, | 84 |
| abstract_inverted_index.systolic, | 118 |
| abstract_inverted_index.tail-cuff | 76 |
| abstract_inverted_index.treatment | 104, 189 |
| abstract_inverted_index.activities | 16 |
| abstract_inverted_index.creatinine | 140 |
| abstract_inverted_index.diastolic, | 119 |
| abstract_inverted_index.exhibiting | 13 |
| abstract_inverted_index.expression | 192, 204 |
| abstract_inverted_index.high-sugar | 45 |
| abstract_inverted_index.increasing | 173, 202 |
| abstract_inverted_index.mechanisms | 35, 101 |
| abstract_inverted_index.protective | 26, 217 |
| abstract_inverted_index.superoxide | 180 |
| abstract_inverted_index.treatment. | 230 |
| abstract_inverted_index.underlying | 34, 100 |
| abstract_inverted_index.Biochemical | 131 |
| abstract_inverted_index.Conclusion: | 207 |
| abstract_inverted_index.Spontaneous | 39 |
| abstract_inverted_index.ameliorated | 125 |
| abstract_inverted_index.anticancer, | 18 |
| abstract_inverted_index.biochemical | 86 |
| abstract_inverted_index.cholesterol | 147, 156 |
| abstract_inverted_index.lipoprotein | 155 |
| abstract_inverted_index.low-density | 154 |
| abstract_inverted_index.nephropathy | 30 |
| abstract_inverted_index.spasmolytic | 22 |
| abstract_inverted_index.administered | 65 |
| abstract_inverted_index.demonstrated | 113 |
| abstract_inverted_index.hypertension | 40 |
| abstract_inverted_index.hypertensive | 29 |
| abstract_inverted_index.investigated | 106 |
| abstract_inverted_index.Introduction: | 0 |
| abstract_inverted_index.interleukin-6 | 162 |
| abstract_inverted_index.significantly | 116 |
| abstract_inverted_index.triglycerides | 149 |
| abstract_inverted_index.malondialdehyde | 164 |
| abstract_inverted_index.pharmacological | 15, 222 |
| abstract_inverted_index.Histopathological | 78 |
| abstract_inverted_index.antihypertensive, | 19 |
| abstract_inverted_index.histopathological | 126 |
| abstract_inverted_index.anti-inflammatory, | 20 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 98 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 13 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7699999809265137 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.8321515 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |